Article Content

Watch these interviews on the iPad edition of this issue conducted by Peter Goodwin

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.
 
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Circulating Free Tumor DNA for EGFR Mutation Testing in NSCLC

 

Martin Reck, MD, PhD, Head of the Departments of Thoracic Oncology and Clinical Trials at Hospital Grosshansdorf in Germany, discusses his study showing an alternative way to test for mutated EGFR in patients with advanced non-small cell lung cancer for whom tissue samples are not available.

 

Anti-BRAF Melanoma Drugs for NSCLC

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Oliver Gautschi, MD, a medical oncologist at Lucern Cantonal Hospital in Switzerland, discusses findings from the retrospective EURAF study, suggesting that many patients with BRAF-mutant lung cancers can benefit from treatment with BRAF inhibitors. Data presented at the conference found that off-label use of melanoma medications targeting BRAF achieved significant response rates in patients with advanced NSCLC.

 

EGFR-TKI-resistant Advanced NSCLC

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Pasi Janne, MD, PhD, Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, discusses his study showing that two thirds of patients with advanced non-small cell lung cancer that has failed to respond to first-line anti-EGFR therapy did respond to the targeted drug AZD9291, now being developed by AstraZeneca.

 

If you are not yet receiving our iPad issues, download the free Oncology Times app from the App Store today! Visithttp://bit.ly/OT-iPadApp, search in the App Store, or follow the link on http://oncology-times.com.

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.